Vir Biotechnology, Inc. (VIR) Stock Analysis — Probabli.AI
AI-powered analysis for VIR (Vir Biotechnology, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $9.10 · Market cap: $1.3B · AI outlook: Bullish
Vir Biotechnology exhibits strong potential for growth propelled by its innovative antiviral pipeline and collaborations. Recent successes in clinical trials and a STRONG BUY analyst consensus make it a compelling opportunity. However, regulatory and clinical execution remains crucial, as setbacks could pose risks. Probabilistic distribution indicates notable upside potential over 1-, 5-, and…
Probabilistic 1-Year Outlook
- Bull 60% · Neutral 25% · Bear 15%
- 1-year price estimates — P10: $7 / P50: $14 / P90: $22
- The strong analyst consensus (STRONG BUY), high price targets, and recent positive developments, including successful trials and collaboration agreements, indicate potential strong near-term upside. However, some mixed…
5-Year Outlook
- Bull 50% · Neutral 35% · Bear 15%
- 5-year price estimates — P10: $9 / P50: $30 / P90: $70
SWOT Highlights
- Strength: Promising antiviral pipeline
- Strength: Strong partnerships and collaborations
- Risk: Limited earnings surprise history
- Risk: Regulatory uncertainties
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
8 Wall Street analysts rate VIR a STRONG BUY with a mean price target of $19.63.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
VIR forecast details · VIR sentiment details · VIR insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.